News

An intensive course in the Lee Silverman Voice Treatment, known as LSVT Loud, may be the best strategy to help people with Parkinson’s disease overcome speech and language problems, according to a trial from the University of Birmingham in the U.K. LSVT Loud, a program of vocal exercises developed…

Once-daily treatment with IRX4204, an oral small molecule being developed by Io Therapeutics, showed a potential to safely ease motor symptoms for most adults with early Parkinson’s disease taking part in a small, 30-day study. Building on this open-label Phase 1 clinical trial (NCT02438215), the company…

AskBio’s investigational gene therapy AB-1005 has been granted fast-track designation for Parkinson’s disease by the U.S. Food and Drug Administration (FDA), and innovation passport designation by the regulatory agency in the U.K. These designations are meant to accelerate the development and review process of therapy candidates designed to…

The first three Parkinson’s disease patients who received a low dose of TED-A9, an investigational stem cell-based therapy being developed by S.Biomedics, saw reduced motor symptoms after a year without any reported side effects. The results come from a small Phase 1/2 clinical study (NCT05887466) where 12…

Scientists have discovered a new regulator — called NHR-49 — that may shed light and open potential new therapeutic avenues to prevent the formation of toxic protein clumps, a hallmark of aging-related diseases, including Parkinson’s disease. Using embryos of the roundworm Caenorhabditis elegans, they found that NHR-49 is activated…

Anew Medical said it will advance clinical development of its Klotho gene therapy program to prevent or stop the progression of neurodegenerative diseases, including Parkinson’s disease. Initial data suggest that maintaining high levels of the Klotho protein in the body may help people live longer and healthier…

Combining gait training with virtual reality and gamification elements — when game-like features are added to non-game activities — may help people with Parkinson’s disease see rehabilitation as a positive experience, a study suggests. That, in turn, could ultimately lead to better motor outcomes for patients, according to researchers.

People with a genetic predisposition to Parkinson’s disease are more likely to have early-onset symptoms, but lifestyle factors such as coffee consumption and tobacco and aspirin use may exert a more significant impact on that risk than common genetic risks, research findings suggest. While still exploratory, “our findings underline…

Mission Therapeutics has received $5.2 million from The Michael J. Fox Foundation (MJFF) and Parkinson’s UK to start clinical testing MTX325, its experimental and neuron-protective oral therapy, in people in the early stages of Parkinson’s disease. “This significant grant, from two of the world’s leading Parkinson’s disease…